Martine Rothblatt Reports Multiple UTHR Sales in September 2025

Rhea-AI Filing Summary

United Therapeutics Form 144 (Rule 144) filing by Martine Rothblatt: The filing notifies proposed sales of 4,000 common shares via TD Securities on 09/16/2025 with an aggregate market value of $1,601,062.04. The shares were originally acquired on 03/15/2016 under an executive deferred compensation arrangement (294,000 shares acquired then) and were exercised via vested options with payment made in common shares. The filer reported multiple prior sales in September 2025 totaling 20,000 shares and gross proceeds shown for each trade.

Positive

• Compliance: The filer used Rule 144 procedures and reported multiple executed trades and a proposed sale through a registered broker (TD Securities).
• Transparency: Specific dates, share counts, and gross proceeds for recent sales are disclosed, enabling investor verification.

Negative

• Insider selling: The filer sold a total of 20,000 shares earlier in September 2025 and proposed an additional 4,000 share sale, which may raise investor concern about insider liquidity.
• Missing plan detail: The filing does not state a Rule 10b5-1 trading plan adoption date, leaving the timing rationale unclear.

Insights

Securities Analyst

TL;DR: Insider has been selling shares in multiple transactions in September 2025; this is a liquidity action rather than disclosure of new company developments.

The filing documents an insider sale program with a proposed block sale of 4,000 shares on 09/16/2025 and prior trades totaling 20,000 shares earlier in the month. The securities were acquired in 2016 under an executive deferred compensation plan and exercised via vested options, indicating standard insider-share mechanics. The disclosed aggregate market values and per-trade proceeds are provided, enabling calculation of realized proceeds and remaining holdings if combined with other disclosures. This disclosure is material as insider trading activity can influence investor perception, but the filing does not state any material operational or financial developments for the company.

Corporate Governance Expert

TL;DR: Multiple insider sales by a named executive were reported; filings include representation regarding absence of undisclosed material information.

The Form 144 shows compliance with Rule 144 reporting for sales aggregated and executed through a broker (TD Securities). The filer affirms no material non-public information exists at signing; no 10b5-1 plan date is provided in the record. From a governance perspective, the pattern of sequential sales across consecutive days and a planned sale date may reflect routine liquidity management. The form lacks details on remaining beneficial ownership or intent beyond the reported transactions.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	TD SECURITIES (USA) LLC 125 PARK AVE, 20Th Floor New York NY 10017	4000	1601062.04	45230000	09/16/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/15/2016	Executive Deferred Compensation	Martine Rothblatt			294000	03/15/2016	Shares exercised via vested options and payment made via common shares

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/09/2025	8000	3188374.33
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/10/2025	4000	1594872.82
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/11/2025	4000	1588904.00
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/12/2025	4000	1615897.79
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/15/2025	4000	1591535.70

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the UTHR Form 144 filed by Martine Rothblatt report?

The form reports a proposed sale of 4,000 common shares on 09/16/2025 valued at $1,601,062.04, and discloses multiple sales earlier in September 2025 totaling 20,000 shares with listed gross proceeds.

How were the shares acquired that are being sold on the UTHR Form 144?

The shares were acquired on 03/15/2016 under an executive deferred compensation arrangement and were exercised via vested options with payment made in common shares.

Through which broker will the proposed UTHR sale be executed?

The proposed sale is listed to be executed through TD Securities (USA) LLC on the NASDAQ exchange.

Does the Form 144 indicate the filer has material non-public information?

By signing, the filer represents they do not know any material adverse information about the issuer that has not been publicly disclosed; no calendar date for a 10b5-1 plan is provided in the filing.

What recent insider sales are disclosed in this filing for UTHR?

The filing lists sales by Martine Rothblatt on 09/09/2025, 09/10/2025, 09/11/2025, 09/12/2025, and 09/15/2025 totaling 20,000 shares with individual gross proceeds shown.